Astrazeneca

What follows the global pandemic? The global vaccine freakout. European politicians have their knickers in a twist about the Oxford-AstraZeneca shot. The source of the panic was reports from Denmark and Norway that some people who received the British-made vaccine developed blood clots — though there is no evidence yet that the shot is at fault. Over a dozen European nations, including France, Germany, Ireland and Spain have temporarily suspended their use of Oxford-AstraZeneca, in what seems to be a team effort to mistake correlation for causation. Sometimes the world cries out for American global leadership. The US is currently sitting on a stockpile of around 30 million doses of the AstraZeneca vaccine. AstraZeneca has yet to apply for FDA approval for their shot.

What to make of the news this morning that Oxford University is to ask for volunteers to take part in a trial to ‘mix and match’ the Pfizer and AstraZeneca vaccines? Researchers will ask for 820 volunteers, all over 50 years old, who will be given two shots of a vaccine, two weeks apart. Some will receive AstraZeneca followed by Pfizer, some the other way around and some — the control group — will be given two doses of the same vaccine. Britain has set itself apart from the EU, not just in the speed and extent of its vaccine procurement programme but also for its willingness to experiment.

The important difference between AstraZeneca's relationship with the UK and its relationship with the EU – and the reason it has fallen behind schedule on around 50m vaccine doses promised to the bloc – is that the UK agreed its deal with AstraZeneca a full three months before the EU did. This gave AstraZeneca an extra three months to sort out manufacturing and supply problems relating to the UK contract (there were plenty of problems). Here is the important timeline. In May AstraZeneca reached an agreement with Oxford and the UK government to make and supply the vaccine. In fact, Oxford had already started work on the supply chain.